Search Results for "Odac Marqibo 2012"
Matching Channels
Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...
ATX-MS-1467 for patients with multiple sclerosis (MS)
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the...
According to the American Brain Tumor Association, just over 24,000 patients will be diagnosed with a primary malignant brain tumour during 2012 in the US alone. Some 80% of primary malignant brain...
Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronavir...
Sequencing platforms in diagnostic laboratories may aid both patient management by detecting resistance associated mutations, and public health measures, by determining phylogenetic relationships be...
Matching News
Class: Chemotherapy Generic Name: Vincristine sulfate liposome injection Trade Name: Marqibo® How is this drug used? Marqibo is used for the treatment of adults withPhiladelphia chromosome-negative (...
Talon CEO: Marqibo US FDA win provides hope for ‘hopeless’ Ph-ALL patients
After winning over two of the most skeptical members of the US FDA's Oncologic Drugs Advisory Committee (ODAC) at a 21 March meeting – panel chairman Dr Wyndham Wilson, chief of lymphoma therap...
FDA approves Marqibo for rare type of leukemia
The FDA has approved Talon Therapeutics’ Marqibo, to treat adult patients with a rare type of leukemia. The US Food and Drug Administration (FDA) has approved Marqibo to treat adults with a rare t...
US FDA approves Talon's Marqibo for rare leukemia
WASHINGTON (Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Talon Therapeutics Inc's Marqibo treatment for adults with Philadelphia chromosome negative acute lymp...
Marqibo Approved for Rare Leukemia
THURSDAY, Aug. 9 -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philad...
U.S. FDA approves Talon's Marqibo for rare leukemia
WASHINGTON (Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Talon Therapeutics Inc's Marqibo treatment for adults with a rare form of leukemia known as Philadelphia c...
FDA approves Talon's Marqibo for rare leukemia
WASHINGTON (Reuters) - The Food and Drug Administration said on Thursday it has approved Talon Therapeutics Inc's Marqibo treatment for adults with a rare form of leukemia known as Philadelphia chromo...
FDA Approves Marqibo for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia
August 9, 2012 -- The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome nega...
Matching PubMed Articles
Vincristine (VCR) is a mainstay of treatment of hematologic malignancies and solid tumors due to its well-defined mechanism of action, demonstrated anticancer activity and its ability to be combined w...
Changing End Points in Breast-Cancer Drug Approval - The Avastin Story.
In December 2007, the Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA) met to discuss the risks and benefits of Genentech's Avastin (bevacizumab) for use in combinat...
Nefrologia 2012;32(6):838-9. doi: 10.3265/Nefrologia.pre2012.Oct.11783. Reply to: Del Pozo et al. Comment on Nefrologia 2012;32(6):837. Nefrologia 2012; 32(4):419-26.
ISS/SIC Donations January 2012 Through June 2012.
Nefrologia 2012;32(6):835-7. doi: 10.3265/Nefrologia.pre2012.Oct.11731. Reply to: Serra Tarragon. Comment on Nefrologia 2012;32(6):835. Nefrologia 2012; 32(4):419-26.
